AstraZeneca PLC's lung cancer therapy Tagrisso (osimertinib) is the first targeted therapy approved by the US Food and Drug Administration for adjuvant treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, an early setting where treatment could make a substantial impact.
"In a year where good news is sometimes hard to come by, I think that this approval is incredibly great...